Braj News Magazine

DelveInsight Business Research LLP

DelveInsight’s “Metastatic Castration-Sensitive Prostate Cancer (mCSPC)- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the mCSPC, historical and forecasted epidemiology as well as the mCSPC market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Metastatic Castration-Sensitive Prostate Cancer Overview

 Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of the male reproductive system. Prostate cancer is the 3rd most prevalent type of cancer in the US and the fourth most common worldwide. Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. Treatment options for prostate cancers include mainly hormonal therapies (also known as androgen deprivation therapy, chemotherapy, immunotherapy, radiation therapy, and surgery. For localized or locally advanced prostate cancer active surveillance, surgery, and radiation therapy are the 3 major treatment options. 

Metastatic Castration-Sensitive Prostate Cancer Epidemiology Insights

• Prostate cancer is the third most prevalent type of cancer in the US and the fourth most common worldwide. Approximately 1 in 9 men in the US will be diagnosed with prostate cancer at some point in their lives. As per the American Cancer Society, 2019, prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. 

• Based on GLOBOCAN 2020 estimates, 1,414,259 new cases of prostate cancer were reported worldwide in 2020, with a higher prevalence in developed countries. The incidence of prostate cancer worldwide correlates with increasing age, with the average age at the time of diagnosis being 66 years.

• The total prevalent population of prostate cancer in the seven major markets was  7,726,394 cases in 2021. The cases in the 7MM are expected to increase during the study period, i.e., 2019–2032.

• Diagnosed cases of prostate cancer were highest in the United States. The diagnosed cases of Prostate cancer in 2021 in the US were  1,327,642 cases.

• United States accounted for  169,647, 738,038, 1,128,665, 525,093, and 131,171 for the age group ≤ 54 years, 55-64 years, 65-74 years, 75-84 years, and  >84 years in 2021.

• In EU5, the total diagnosed prevalent cases of prostate cancer by clinical stages were around  656,570, 378,363, and 77,898 cases for locally advanced (Stage I–III), biochemical recurrence/progressive, and metastatic, respectively in 2021.

• Among EU5 countries, Germany had the maximum total cases of Metastatic Castration Sensitive Prostate Cancer with  14,600 cases in 2021 while Spain accounted for the least number of cases. Spain accounted for  4,381 cases of metastatic CSPC in 2021. The Treated cases of Metastatic Castration Sensitive Prostate Cancer in Japan were  11,094  in 2021.

Click here to learn more about the Metastatic Castration-Sensitive Prostate Cancer Market Landscape

 The Report Covers the Metastatic Castration-Sensitive Prostate Cancer Epidemiology Segmented by:

• Total Metastatic Castration-Sensitive Prostate Cancer prevalent cases  

• Total Metastatic Castration-Sensitive Prostate Cancer age-specific cases 

• Total Metastatic Castration-Sensitive Prostate Cancer treated cases 

• Total Eye Neoplasm diagnosed cases 

 Metastatic Castration-Sensitive Prostate Cancer Market Outlook 

Metastatic Castration Sensitive Prostate Cancer in literature refers to prostate cancer that still responds to testosterone suppression therapy. Moreover, patients with newly diagnosed metastatic disease and high-risk disease characteristics tend to have a poorer prognosis. In 2018, Zytiga (abiraterone acetate) in combination with prednisone was approved for the treatment of metastatic high-risk CSPC. Approval in this category was based on the results of the Phase III LATITUDE trial. Before this, Zytiga was approved in 2011 initially for patients with mCRPC who had received prior chemotherapy and expanded the indication in 2012 for patients with mCRPC.Moreover, In September 2019, the US FDA also approved Erleada for patients with mHSPC. The efficacy of Erleada was evaluated in TITAN Trial. The findings of this trial have shown statistically significant improvements in both OS and rPFS. At the time of a prespecified interim analysis, the hazard ratio for overall survival was 0.67, and median overall survival was not reached in either arm. The hazard ratio for the rPFS improvement was 0.48. The median rPFS was not reached with enzalutamide plus ADT and was 22.1 months with placebo plus ADT. According to DelveInsight, the Metastatic Prostate Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Metastatic Castration-Sensitive Prostate Cancer Market

Astellas Pharma

Pfizer

Janssen Pharmaceutical

Myovant Sciences

Takeda

Bayer

Merck

Clovis Oncology

Bristol-Myers Squibb

Novartis Pharmaceuticals

Ferring Pharmaceuticals

GenentechExelixis

And many others 

Metastatic Castration-Sensitive Prostate Cancer Therapies Covered and Analyzed in the Report:

• Xtandi

• Erleada 

• Orgovyx 

• Talazoparib 

• Nubeqa

• Keytruda

• Niraparib 

• Rubraca 

• Opdivo

• Capivasertib

• 177Lu-PSMA-617 

• Firmagon

• Tecentriq 

And many others 

Learn more about the Key Companies and Emerging Therapies in the Metastatic Castration-Sensitive Prostate Cancer Market

 Table of Contents 

1.  Key Insights 

2.  Metastatic Castration-Sensitive Prostate Cancer Introduction 

3.  Executive Summary of  Metastatic Castration-Sensitive Prostate Cancer       

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  Metastatic Castration-Sensitive Prostate Cancer Emerging Therapies

7.  Metastatic Castration-Sensitive Prostate Cancer Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn about the detailed offerings of the report @ Metastatic Castration-Sensitive Prostate Cancer Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services